ALLARITY THERAPEUTICS INC (ALLR)
US0167444019 - Common Stock
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
These stocks are moving in today's pre-market session
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We are starting the trading week with a dive into the biggest pre-market stock movers worth keeping tabs on for Monday morning!
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Why Is Applied Digital (APLD) Stock Down 6% Today?
Applied Digital stock fell on Friday as APLD investors react to the company missing EPS and revenue estimates in fiscal Q3 2024.
Why Is Motus GI (MOTS) Stock Down 37% Today?
Motus GI stock is falling hard on Friday following a delisting notice for MOTS shares that the company doesn't intend to appeal.
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on stock movements.
Stay updated with the stocks that are on the move in Friday's pre-market session.
Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today?
Allarity Therapeutics stock is up on Monday alongside heavy trading of ALLR shares on a prospectus update from the company.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Friday is here and we're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers this morning!
What's going on in today's session
Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Top movers in Tuesday's session
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Tuesday's session: gap up and gap down stocks
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Get insights into the top gainers and losers of Monday's after-hours session.
Get insights into the top gainers and losers of Monday's after-hours session.
In today's session, these stocks are experiencing unusual volume.
Let's have a look at what is happening on the US markets on Monday. Below you can find the stocks with an unusual volume in today's session.
Top movers in Friday's after hours session
After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
Boston (April 4, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to...
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources to accelerate...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers on Tuesday as we check out all of the hottest news moving shares this morning!
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
Boston (March 25, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to...
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
Leadership Changes Led by Appointment of Co-Founder Thomas Jensen as Interim CEO and Jeremy Graff, Ph.D., former Eli Lilly Executive, as Executive...
Allarity Therapeutics to Present at Biomarkers 2024
Allarity Therapeutics to Present at Biomarkers 2024
Boston (February 28, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to...
Allarity Therapeutics appoints co-founder Thomas Jensen as interim CEO (NASDAQ:ALLR)
Allarity Therapeutics announces appointment of Thomas Jensen as interim CEO, and Jeremy R.
Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor
Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor
Boston (December 12, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company developing...